Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women.

Centers for Disease Control and Prevention, Mailstop E-45 Division of HIV/AIDS, 1600 Clifton Road NE, Atlanta, GA 30333, USA.
JAIDS Journal of Acquired Immune Deficiency Syndromes (Impact Factor: 4.39). 02/2003; 32(2):203-9. DOI: 10.1097/00126334-200302010-00013
Source: PubMed

ABSTRACT Data on the incidence and prognostic significance of renal dysfunction in HIV disease are limited.
To determine the incidence of proteinuria and elevated serum creatinine in HIV-positive and HIV-negative women and to determine whether these abnormalities are predictors of mortality or associated with causes of death listed on the death certificate in HIV-positive women.
The incidence of proteinuria or elevated serum creatinine and mortality was assessed in a cohort of 885 HIV-positive women and 425 at-risk HIV-negative women.
Women from the general community or HIV care clinics in four urban locations in the United States.
Creatinine of >or=1.4 mg/dL, proteinuria 2 or more, or both. Deaths confirmed by a death certificate (92%) or medical record/community report (8%).
At baseline, 64 (7.2%) HIV-positive women and 10 (2.4%) HIV-negative women had proteinuria or elevated creatinine. An additional 128 (14%) HIV-positive women and 18 (4%) HIV-negative women developed these abnormalities over the next (mean) 21 months. Relative hazards of mortality were significantly increased (adjusted relative hazard = 2.5; 95% confidence interval: 1.9-3.3), and there were more renal causes recorded on death certificates (24/92 (26%) vs. 3/127 (2.7%), p<.0001) in HIV-infected women with, compared with those without these renal abnormalities.
Proteinuria, elevated serum creatinine, or both frequently occurred in these HIV-infected women. These renal abnormalities in HIV-infected women are associated with an increased risk of death after controlling for other risk factors and with an increased likelihood of having renal causes listed on the death certificate. The recognition and management of proteinuria and elevated serum creatinine should be a priority for HIV-infected persons.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Few studies have compared the incidence of end-stage renal disease (ESRD) among individuals with the human immunodeficiency virus (HIV) and diabetes. We followed a national sample of 2,015,891 US veterans over a median peroid of 3.7 years for progression to ESRD. The age- and sex-adjusted incidence of ESRD (per 1000 person-years) among HIV-infected black patients was nearly an order of magnitude higher than among HIV-positive white patients, almost twice that of diabetic whites, and similar to that among diabetic blacks. In multivariate Cox proportional hazards analysis, diabetes was associated with an increased risk of ESRD among white patients, but HIV was not. Among black individuals, however, both HIV and diabetes conferred a similar increase in the risk of ESRD (4- to 5-fold increase compared to white individuals without HIV or diabetes). HIV and diabetes carry a similar risk of ESRD among black patients, highlighting the importance of developing strategies to prevent and treat renal disease among HIV-infected black individuals.
    Journal of the American Society of Nephrology 12/2007; 18(11):2968-74. DOI:10.1681/ASN.2007040402 · 9.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.
    Clinical Infectious Diseases 09/2014; 59(9). DOI:10.1093/cid/ciu617 · 9.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: To determine the relationships among intrarenal and systemic inflammation to renal disease in HIV. Methods: We compared paired serum and urinary levels (normalized to urine creatinine) of MCP-1, RANTES, IP-10, IL-8, and B2M between two groups of HIV-infected subjects not receiving antiretroviral therapy [A: not expecting to initiate ART immediately due to having CD4 cell counts ≥ 350/µL, N=26; B: about to initiate ART, N=19], a group of HIV-infected subjects receiving virologically-suppressive antiretroviral therapy [C, N=30], and a group of HIV-uninfected, healthy volunteers [D, N=45]. We then correlated these inflammatory biomarker levels with urine protein/creatinine ratios (uPCR), urine albumin/creatinine ratios (uACR), and estimated glomerular filtration rates (eGFR). Results: Urine inflammatory biomarker levels were highest in Group B. When combining all 4 study groups, statistically significant positive correlations included uPCR with urine IL-8, urine MCP-1, urine IP-10, and serum IP-10 and uACR with urine IL-8, urine B2M, serum IP-10, and serum B2M. eGFR was statistically significantly negatively correlated with serum MCP-1 and serum B2M. Paired serum and urine levels of IP-10 and B2M (but not IL-8, RANTES, or MCP-1) were significantly correlated with each other in the overall group. Conclusions: The levels of urine inflammatory markers tested differed by HIV status and use of virologically suppressive ART. These urine and serum inflammatory markers were differentially correlated with uPCR, uACR, and eGFR, suggesting different intrarenal and systemic inflammatory pathways may contribute to different measures of nephropathy.
    AIDS Research and Human Retroviruses 02/2015; 31(4). DOI:10.1089/AID.2014.0234 · 2.46 Impact Factor